Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease · Genitourinary Tuberculosis

Understanding Pathology and Lab Reports in Genitourinary TB

At a Glance

A negative AFB stain does not rule out genitourinary tuberculosis because the disease often has very few bacteria in tissue. Doctors combine pathology with NAAT, culture, and drug-susceptibility results to confirm TB and choose effective medicines.

When you receive a pathology or lab report for suspected genitourinary tuberculosis (GUTB), the language can be dense and confusing. These reports are the “detective work” your care team uses to confirm the presence of Mycobacterium tuberculosis and, crucially, to determine which medications will kill it [1][2].

Because GUTB is often a “paucibacillary” disease—meaning there are very few bacteria present in the tissue—your reports may contain several different types of tests to ensure nothing is missed [3][4].

The Pathologist’s View: What’s in the Tissue?

If you had a biopsy of your kidney, bladder, or reproductive organs, a pathologist looked at the tissue under a microscope. They are looking for a specific pattern of inflammation.

  • Caseating Granulomas: This is a classic finding of TB [5][6]. A granuloma is an organized ball of immune cells the body builds to wall off the bacteria. Caseating (from the Latin word for cheese) means the center of that ball contains soft, “cheesy” dead tissue [5][7].
  • Multinucleated Giant Cells: You may see “Langhans-type giant cells” mentioned [8][9]. These are large immune cells formed by several smaller cells fusing together to fight the infection.
  • Important Caveat: Caseating granulomas and Langhans-type giant cells are not 100% specific for TB. Fungal and other infections, inflammatory disease, and occasionally other conditions can produce granulomatous or necrotizing inflammation. Histology supports but does not by itself confirm TB, and negative histology does not exclude it [10].
  • Necrosis and Fibrosis: In chronic cases, the report may describe necrosis (tissue death) and fibrosis (scarring), which show how the infection has affected the organ’s structure over time [5].

The Mystery of the “Negative” AFB Stain

Your report might state “AFB Negative.” While this sounds like good news, it does not rule out tuberculosis.

  • What is an AFB Stain? Acid-Fast Bacilli (AFB) are bacteria that hold onto a specific red or glowing dye even when washed with acid. TB bacteria are the most famous example [3][11].
  • Why it’s often negative: In GUTB, there are often so few bacteria that they are simply not in the tiny slice of tissue on the microscope slide [3]. In one specific study of epididymal TB, the AFB stain was negative in over 73% of confirmed cases [3].
  • What it means for you: AFB stains have limited sensitivity in paucibacillary disease. A negative AFB stain is common in GUTB. Your doctor will look at the NAAT (DNA test) or the culture results to get a more definitive answer [3][12].

Drug Susceptibility Testing (DST): The Map for Treatment

Determining which drugs will work is crucial for your care plan.

  • The Goal: The lab “challenges” your specific strain of TB with the standard antibiotics—Isoniazid, Rifampin, Ethambutol, and Pyrazinamide [13][14].
  • Why it matters: If your strain is resistant to any of these drugs, the standard 6-month treatment may fail [15][14].
  • Genotypic vs. Phenotypic: You may see “Genotypic” results (like the Xpert MTB/RIF test), which look for DNA mutations that predict resistance and can provide early answers [4][16]. “Phenotypic” results come from the culture and show an in-vitro prediction of whether the drugs kill the bacteria [13]. Both must be interpreted by a TB expert.
  • Warning: Rifampin resistance requires urgent specialist/public-health evaluation for possible drug-resistant TB, and the standard regimen should not be changed independently.

Your Lab Report Completeness Checklist

When reviewing your records with your doctor, use this checklist to understand what tests were done:

  1. [ ] Histology: Does the report mention granulomatous inflammation or caseous necrosis? [5]
  2. [ ] Malignancy Check: Was the specimen adequate to evaluate for malignancy? A small or poorly targeted biopsy can miss malignancy, and a negative sample must be interpreted with imaging and clinical findings [17][8].
  3. [ ] NAAT/PCR: Was a rapid DNA test (like GeneXpert) performed on the tissue or urine? [4][16]
  4. [ ] Culture: Has a mycobacterial culture been started? (Remember, this can take 6-8 weeks). [18][13]
  5. [ ] Drug Susceptibility (DST): Has the lab tested (or will they test) which drugs work best against your strain? [15][14]
  6. [ ] Resistance Status: Does the report specifically mention “Rifampin resistance” (Detected or Not Detected)? [4]

Common questions in this guide

What do caseating granulomas mean on a genitourinary TB biopsy?
Caseating granulomas are a pattern of organized inflammation with dead tissue in the center, and they can support a diagnosis of tuberculosis. They are not unique to TB, because fungal infections, other infections, and inflammatory conditions can cause similar findings. Doctors interpret the biopsy with molecular tests, cultures, imaging, and the clinical picture.
Can a negative AFB stain rule out genitourinary tuberculosis?
No. Genitourinary TB often has very few bacteria in the tissue, so the bacteria may not be present in the small sample examined under the microscope. A negative AFB stain is common and must be considered alongside NAAT or PCR results, culture, and other clinical evidence.
What is the difference between a TB NAAT and a culture?
A NAAT, or nucleic acid amplification test, looks for TB genetic material and can provide a rapid result. A mycobacterial culture attempts to grow the bacteria and may take six to eight weeks, but it can provide material for drug susceptibility testing. Both results help clinicians confirm TB and plan treatment.
What does drug susceptibility testing show in genitourinary TB?
Drug susceptibility testing helps determine whether the TB strain is likely to respond to medicines such as isoniazid, rifampin, ethambutol, and pyrazinamide. Genotypic tests look for genetic changes linked to resistance, while phenotypic testing uses culture to assess how the bacteria respond to medicines. A TB expert should interpret these results.
What should I do if my report says rifampin resistance was detected?
Detected rifampin resistance requires urgent evaluation by a TB or infectious disease specialist and public health authorities because it may indicate drug-resistant tuberculosis. Do not start, stop, or change TB medicines on your own while the result is being evaluated.
Can a negative biopsy rule out cancer or another condition?
No. A small or poorly targeted biopsy can miss malignancy or another condition that resembles TB. A negative sample should be interpreted with imaging, the adequacy of the specimen, and the rest of your clinical findings.

Get notified when new evidence is published on Primary genito-urinary tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Genitourinary Tuberculosis: A Brief Manual for Urologists on Diagnosis and Treatment from the European Association of Urology Urological Infections Panel.

    Bausch K, Mantica G, Smith EJ, et al.

    European urology focus 2024; (10(1)):77-79 doi:10.1016/j.euf.2023.07.006.

    PMID: 37541917
  2. 2

    Genital tuberculosis: current status of diagnosis and management.

    Yadav S, Singh P, Hemal A, Kumar R

    Translational andrology and urology 2017; (6(2)):222-233 doi:10.21037/tau.2016.12.04.

    PMID: 28540230
  3. 3

    Using ultrasound guided needle biopsy in conjunction with GeneXpert MTB/RIF to diagnose epididymal tuberculosis.

    Cui J, Li X, Yu Y, et al.

    Medicine 2023; (102(52)):e36344 doi:10.1097/MD.0000000000036344.

    PMID: 38206740
  4. 4

    Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

    Kohli M, Schiller I, Dendukuri N, et al.

    The Cochrane database of systematic reviews 2018; (8()):CD012768 doi:10.1002/14651858.CD012768.pub2.

    PMID: 30148542
  5. 5

    Silent Renal Autodestruction: Incidental Discovery of End-Stage Genitourinary Tuberculosis (Putty Kidney) 14 Years After Treatment for Pulmonary Tuberculosis With Multisystem Sequelae.

    Kurale M, Chaudhary S, Nimje R

    Cureus 2026; (18(7)):e113227 doi:10.7759/cureus.113227.

    PMID: 42633409
  6. 6

    Imaging findings of prostate tuberculosis by transrectal contrast-enhanced ultrasound and comparison with 2D ultrasound and pathology.

    Yang G, Ruan L

    The British journal of radiology 2022; (95(1129)):20210713 doi:10.1259/bjr.20210713.

    PMID: 34586884
  7. 7

    Hidden in Plain Sight: Peritoneal Tuberculosis Mimicking Ovarian Neoplasm-A Case Report.

    Romero-Rojas DS, Rojas-Torres A, Amell-Barón B, et al.

    Tropical medicine and infectious disease 2025; (10(12)) doi:10.3390/tropicalmed10120346.

    PMID: 41441583
  8. 8

    Isolated Tuberculous Testicular Abscess Without Systemic Involvement: A Rare Cause of Scrotal Swelling.

    Varshney B, Agarwal S, Joshi YR

    Ochsner journal 2026; (26(3)):266-269 doi:10.31486/toj.26.0012.

    PMID: 42746475
  9. 9

    Isolated Testicular Tuberculosis Mimicking a Testicular Tumor: A Case Report and Review of the Literature.

    Zhan TP, Li XS, Shang PF

    Case reports in surgery 2026; (2026()):3676762 doi:10.1155/cris/3676762.

    PMID: 42571306
  10. 10

    Histopathologic review of granulomatous inflammation.

    Shah KK, Pritt BS, Alexander MP

    Journal of clinical tuberculosis and other mycobacterial diseases 2017; (7()):1-12 doi:10.1016/j.jctube.2017.02.001.

    PMID: 31723695
  11. 11

    Genitourinary Tuberculosis Presenting As Testicular Malignancy and Resulting in Tuberculous Autonephrectomy.

    Lodeikina V, Kuksa L, Ozere I, Riekstins R

    Cureus 2026; (18(6)):e111687 doi:10.7759/cureus.111687.

    PMID: 42529006
  12. 12

    Assessing the diagnostic accuracy of the Xpert MTB/RIF assay in detecting epididymal tuberculosis.

    Liu P, Liu Y, Wang Y, et al.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2022; (41(4)):615-620 doi:10.1007/s10096-022-04418-3.

    PMID: 35128582
  13. 13

    Multicentre evaluation of Xpert MTB/RIF assay in detecting urinary tract tuberculosis with urine samples.

    Chen Y, Wu P, Fu L, et al.

    Scientific reports 2019; (9(1)):11053 doi:10.1038/s41598-019-47358-3.

    PMID: 31363115
  14. 14

    Medical treatment for urogenital tuberculosis (UGTB).

    Wejse C

    GMS infectious diseases 2018; (6()):Doc04 doi:10.3205/id000039.

    PMID: 30671335
  15. 15

    Analysis of epidemiological characteristics of extrapulmonary tuberculosis from South-Central China.

    Yu Y, Xiang Y, Liu H, et al.

    Frontiers in public health 2024; (12()):1405358 doi:10.3389/fpubh.2024.1405358.

    PMID: 39086797
  16. 16

    Clinical validation of urine-based Xpert® MTB/RIF assay for the diagnosis of urogenital tuberculosis: A systematic review and meta-analysis.

    Chen K, Malik AA, Nantasenamat C, et al.

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2020; (95()):15-21 doi:10.1016/j.ijid.2020.03.023.

    PMID: 32194240
  17. 17

    BCGitis or genitourinary tuberculosis? Diagnostic dilemma following intravesical Bacillus Calmette-Guérin therapy: a case report.

    Lamichhane A, Sharma S, Gautam P, et al.

    Annals of medicine and surgery (2012) 2026; (88(7)):4564-4567 doi:10.1097/MS9.0000000000005227.

    PMID: 42433746
  18. 18

    Diagnostic pitfalls of urogenital tuberculosis.

    Chandran S, Rahman A, Norris JM, et al.

    Tropical medicine & international health : TM & IH 2021; (26(7)):753-759 doi:10.1111/tmi.13583.

    PMID: 33817915

This page is for informational purposes only and does not constitute medical advice. Your TB or infectious disease specialist, urologist, and pathologist should interpret your genitourinary TB results and guide treatment.